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A B S T R A C T
Sporadic cerebral amyloid angiopathy (CAA) is a very common small vessel disease of the brain, showing
preferential and progressive amyloid-βdeposition in the wall of small arterioles and capillaries of the
leptomeninges and cerebral cortex. CAA now encompasses not only a speciﬁc cerebrovascular pathological
trait, but also diﬀerent clinical syndromes - including spontaneous lobar intracerebral haemorrhage (ICH),
dementia and ‘amyloid spells’ - an expanding spectrum of brain parenchymal MRI lesions and a set of diagnostic
criteria – the Boston criteria, which have resulted in increasingly detecting CAA during life. Although currently
available validated diagnostic criteria perform well in multiple lobar ICH, a formal diagnosis is currently lacking
unless a brain biopsy is performed. This is partly because in practice CAA MRI biomarkers provide only indirect
evidence for the disease. An accurate diagnosis of CAA in diﬀerent clinical settings would have substantial
impact for ICH risk stratiﬁcation and antithrombotic drug use in elderly people, but also for sample homogeneity
in drug trials. It has recently been demonstrated that vascular (in addition to parenchymal) amyloid-βdeposition
can be detected and quantiﬁed in vivo by positron emission tomography (PET) amyloid tracers. This non-
invasive approach has the potential to provide a molecular signature of CAA, and could in turn have major
clinical impact. However, several issues around amyloid-PET in CAA remain unsettled and hence its diagnostic
utility is limited. In this article we systematically review and critically appraise the published literature on
amyloid-PET (PiB and other tracers) in sporadic CAA. We focus on two key areas: (a) the diagnostic utility of
amyloid-PET in CAA and (b) the use of amyloid-PET as a window to understand pathophysiological mechanism
of the disease. Key issues around amyloid-PET imaging in CAA, including relevant technical aspects are also
covered in depth. A total of six small-scale studies have addressed (or reported data useful to address) the
diagnostic utility of late-phase amyloid PET imaging in CAA, and one additional study dealt with early PiB
images as a proxy of brain perfusion. Across these studies, amyloid PET imaging has deﬁnite diagnostic utility
(currently tested only in probable CAA): it helps rule out CAA if negative, whether compared to healthy controls
or to hypertensive deep ICH controls. If positive, however, diﬀerentiation from underlying incipient Alzheimer's
disease (AD) can be challenging and so far, no approach (regional values, ratios, visual assessment) seems
suﬃcient and speciﬁc enough, although early PiB data seem to hold promise. Based on the available evidence
reviewed, we suggest a tentative diagnostic ﬂow algorithm for amyloid-PET use in the clinical setting of
suspected CAA, combining early- and late-phase PiB-PET images. We also identiﬁed ten mechanistic amyloid-
PET studies providing early but promising proof-of-concept data on CAA pathophysiology and its various
manifestations including key MRI lesions, cognitive impairment and large scale brain alterations. Key open
questions that should be addressed in future studies of amyloid-PET imaging in CAA are identiﬁed and
highlighted.
1. Introduction
Sporadic cerebral amyloid angiopathy (CAA) is a very common
small vessel disease (SVD) of the brain, a key cause of spontaneous
lobar intracerebral haemorrhage (ICH) and a potential contributor to
age- and Alzheimer pathology-related cognitive decline (Boulouis et al.,
http://dx.doi.org/10.1016/j.nicl.2017.05.002
Received 17 February 2017; Received in revised form 2 May 2017; Accepted 4 May 2017
⁎ Corresponding author at: Department of Neurology, Sainte-Anne Hospital, Inserm U894, Paris Descartes University, Paris, France.
1 Equal contribution.
E-mail address: jean-claude.baron@inserm.fr (J.-C. Baron).
NeuroImage: Clinical 15 (2017) 247–263
Available online 05 May 2017
2213-1582/ © 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
2016; Charidimou et al., 2012a; Viswanathan and Greenberg, 2011).
CAA has thus received increasing attention in the both the Alzheimer
and the stroke community for a number of additional important clinical
reasons. In Alzheimer's disease there is likely a close relationship
between CAA and the risk of amyloid-related imaging abnormalities
(ARIA), the main dose-limiting adverse event to immunization against
amyloid. ARIA shares important features with the CAA-related inﬂam-
mation syndrome. In stroke, the presence of lobar cerebral microbleeds,
and even more of cortical superﬁcial siderosis – both putative CAA
markers – may be associated with increased risk of future haemorrhage,
including spontaneous lobar ICH, anticoagulation-related ICH and post-
thrombolysis ICH.
The neuropathological hallmark of CAA is vascular amyloid-β
deposition in the wall of small arterioles and capillaries of the
leptomeninges and cerebral cortex, with or without involving the
adjacent parenchyma. White matter small vessels, long cortical pene-
trators and deep arterial perforators (i.e. in the basal ganglia and
thalami) do not typically show amyloid deposition. CAA should be
viewed as a chronic degenerative protein-elimination failure process
(Carare et al., 2013), in which the medial layer of arterioles undergoes
progressive loss of smooth muscle cells with parallel deposition of
amyloid, causing both haemorrhagic and ischemic lesions (Attems
et al., 2011). This is mostly composed of the more soluble, amyloid-
β40 species, in contrast to Alzheimer's disease amyloid plaques,
primarily composed of amyloid-β42 species (Charidimou et al.,
2012a). The vessels aﬀected by CAA can show secondary (so-called
vasculopathic changes), including ﬁbrinoid necrosis, wall thickening,
microaneurysm formation, and perivascular blood-breakdown products
deposition (Love et al., 2014). The severity and extent of histological
changes in CAA is often patchy (Vinters, 1987), whereby foci of vessels
severely aﬀected by CAA may be adjacent to other vessel segments with
mild or absent amyloid-β deposition (Attems et al., 2011; Vinters,
1987). The regional topographical distribution typically favours poster-
ior lobar brain regions (especially the occipital lobes and the temporal-
parietal regions). During the course of the disease, CAA pathology
progresses to more anterior lobar areas (Reijmer et al., 2016b). The
cerebellum may also be occasionally aﬀected (Vinters, 1987).
Results from population-based autopsy studies suggest that CAA of
any neuropathological degree occurs in about 20–40% in non-demen-
ted, and 50–60% in demented elderly populations (age range for both
groups 70–90 years) (Keage et al., 2009). Moderate-to-severe CAA
occurs in about 7–24% and 30–40% of non-demented and demented
older groups respectively (Keage et al., 2009). In Alzheimer's disease
brains, any degree of CAA is identiﬁed in a high proportion of cases
(85–95%) when sought thoroughly, often involving, at times even
preferentially, the capillaries (Jellinger, 2002; Kalaria and Ballard,
1999). Nevertheless, in most these older individuals, CAA is asympto-
matic and a relatively small proportion is diagnosed during life with
CAA-related clinical symptomatology. CAA is most often suspected in
life by symptomatic lobar (i.e. cortical-subcortical) ICH, especially
involving the occipital and posterior parieto-temporal lobes (Rosand
et al., 2005). Multiple recurrent CAA-related ICH can then occur over
months or years (at a recurrence rate around 10%/year) (Biﬃ et al.,
2010), with progressive neurologic decline and high risk of death. CAA
is also associated with characteristic markers of SVD on clinical MRI,
including lobar cerebral microbleeds and cortical superﬁcial siderosis
on T2*-GRE/SWI MRI, white matter hyperintensities and cortical
microinfarcts on T2-weighted/FLAIR sequences, and MRI-visible peri-
vascular spaces in the centrum semiovale on T2-weighted imaging
(Greenberg et al., 2014). The presence of multiple strictly lobar
microbleeds are accepted as one of the hallmark biomarkers for CAA
presence and are useful for CAA diagnosis within the Boston criteria
(Knudsen et al., 2001; Linn et al., 2010) (Table 1).
In this setting, the original Boston criteria for “probable CAA-related
ICH” requires the occurrence of two symptomatic lobar ICHs or one
symptomatic lobar ICH and the presence of ≥1 strictly lobar cerebral
microbleed in a patient ≥55 years old, other potential causes being
excluded (Knudsen et al., 2001). “Probable CAA-related ICH” is the
category pointing to the highest certainty for CAA diagnosis within the
Boston criteria, with sensitivity ~90% and speciﬁcity ~80–85%. The
addition of cortical superﬁcial siderosis as another haemorrhagic
marker was recently shown to improve the sensitivity of these criteria
(i.e. revised Boston criteria) (Linn et al., 2010). Similar criteria have
now been validated against CAA-proven histopathology even in in-
dividuals presenting without ICH in a hospital-based setting: speciﬁ-
city> 90% and positive predictive value> 87% in the presence of≥2
strictly lobar CMBs, and no other cause identiﬁed (Martinez-Ramirez
et al., 2015). This is of particular clinical relevance, as CAA is
increasingly recognized to present without overt ICH, including tran-
sient focal neurological episodes (‘amyloid spells’) (Charidimou et al.,
2013a; Charidimou et al., 2012b) often associated with acute convexity
subarachnoid haemorrhage, focal seizures or cognitive impairment and
dementia. CAA may also be an incidental diagnosis in patients with
ischaemic stroke, in which it is considered an important risk factor for
ICH related to oral anticoagulants and thrombolysis-related haemato-
mas (Charidimou et al., 2015d; Mattila et al., 2015). However, CAA
diagnosis in patients without ICH and low CMBs counts or patients with
only a single lobar ICH (i.e. “possible CAA” as per Boston criteria)
remains challenging and with relatively low speciﬁcity. In any case, a
Table 1
Boston criteria for the diagnosis of CAA. Classic criteria are based only on the presence of
lobar CMBs and ICH (not cSS).
Deﬁnite CAA Full post-mortem examination demonstrating:
− Lobar, cortical or corticosubcortical haemorrhage/
microbleed
− Severe CAA with vasculopathy
− Absence of other diagnostic lesion
Probable CAA with
supporting
pathology
Clinical data and pathologic tissue (evacuated
hematoma or cortical biopsy) demonstrating
− Lobar, cortical or corticosubcortical haemorrhage/
microbleed
− Some degree of CAA in specimen
− Absence of other diagnostic lesion
Probable CAA Clinical data and MRI or CT demonstrating
− Multiple haemorrhages/microbleeds restricted to
lobar, cortical or corticosubcortical regions
(cerebellar haemorrhage allowed)
OR
− Single lobar, cortical or corticosubcortical
haemorrhage/microbleed and focal or
disseminated superﬁcial siderosisa
AND
Age≥ 55 years
AND
Absence of other cause of haemorrhage or
superﬁcial siderosis
Possible CAA Clinical data and MRI or CT demonstrating
− Single lobar, cortical or corticosubcortical
haemorrhage/microbleed
OR
− Focal or disseminated superﬁcial siderosisa
AND
Age≥ 55 years
AND
Absence of other cause of haemorrhage or
superﬁcial siderosis
a The revised Boston criteria incorporate cSS in patients presenting with lobar ICH.
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deﬁnite diagnosis still rests on autopsy as the gold standard, while
biopsy samples of adequate quality can provide further support for CAA
diagnosis (‘probable CAA with supportive pathology’) (Knudsen et al.,
2001).
While the clinical-imaging spectrum of CAA has been expanded and
reﬁned substantially with the broad availability of brain MR imaging
(Boulouis et al., 2016), imaging biomarkers of brain parenchymal
microvascular lesions provide only indirect evidence for the disease.
Since symptomatic or asymptomatic CAA presentations with or without
ICH are becoming increasingly common clinical scenaria, additional
non-invasive techniques and more direct biomarkers to diagnose CAA
in vivo would have major clinical impact. Such a biomarker would be
particularly useful for detecting CAA pathology in patients where the
diagnosis is currently uncertain. Examples would include single lobar
ICH without microbleeds (possible CAA), mixed location of haemor-
rhagic lesions (ICH and/or CMBs in both lobar and deep areas, the latter
being associated with chronic arterial hypertension and other vascular
risk factors), as well as strictly lobar microbleeds or cortical superﬁcial
siderosis in people with a history of ischemic stroke, isolated cognitive
impairment or subacute encephalopathy, or even asymptomatic (e.g.,
patients with atrial ﬁbrillation considered for anticoagulation). Of note,
even in the setting of probable CAA-ICH by the Boston criteria, these is
still an element of uncertainty, especially in ‘borderline’ cases with one
lobar ICH and only one or two lobar microbleeds. Also, the Boston
criteria require ‘all other ICH causes to be excluded’ (Table 1), which is
often not straightforward in clinical practice, since many factors could
potentially contribute to a symptomatic ICH or to lobar microbleeds, on
top of lowering the threshold for CAA expression. Along this line, in the
elderly brain hypertensive arteriopathy often co-exists with CAA and
can also lead to (or strongly facilitate) lobar ICH and CMBs. A
molecular diagnosis would be very useful across diﬀerent patient
populations. This would have substantial individual clinical impact in
risk stratiﬁcation for anticoagulants or antithrombotic drug adminis-
tration in elderly people with vascular risk factors, ischaemic events,
atrial ﬁbrillation, or spontaneous ICH and small vessel disease in
general, but also for appropriate selection of patients for drug trials
and other clinical studies and for monitoring of drug eﬀects.
Vascular amyloid-β can be detected and quantiﬁed on positron
emission tomography (PET) scanning with the amyloid radioligand
tracer 11C-labelled Pittsburgh Compound B (PiB), and might thus serve
as a direct, molecular marker of underlying CAA. Although PiB was
initially developed to label parenchymal amyloid-β deposits in
Alzheimer's disease, it also labels cerebrovascular amyloid (Bacskai
et al., 2002). A radiologic-pathologic study showed high cortical PiB-
PET retention in a patient diagnosed with Lewy body dementia, in
whom post-mortem amyloid immunohistochemistry three months later
revealed only moderate parenchymal amyloid plaque number, but
abundant vascular amyloid deposition (Bacskai et al., 2007). A number
of small early studies have reported positive PiB-PET in non-demented
patients with pathology-proven sporadic or mutation-proven familial
CAA (Greenberg et al., 2008; Johnson et al., 2007). This raised the
potentially exciting prospect of making a CAA diagnosis in living
subjects with high sensitivity and speciﬁcity using amyloid imaging
and without the need for a brain biopsy in the appropriate clinical
setting. However, healthy controls also frequently show abnormally
high PiB uptake thought to reﬂect incipient Alzheimer pathology
(Mintun et al., 2006; Rowe et al., 2013), pointing to potentially limited
diagnostic utility of amyloid PET in CAA due to poor speciﬁcity, while
the diﬀerentiation between CAA- and AD-related abnormally high PiB
uptake is another potential source of reduced speciﬁcity (Baron et al.,
2014). Apart from its diagnostic potential, amyloid PET imaging is
increasingly used in CAA research to directly test pathophysiological/
mechanistic hypotheses on CAA-related brain lesions, including hae-
morrhagic markers (Dierksen et al., 2010; Gurol et al., 2012) and the
underlying presumed pathology, i.e. cerebrovascular amyloid.
In this article, we aim to systematically review and critically
appraise the published literature on amyloid-PET (PiB and other
tracers) in CAA, using standard ‘late phase’ imaging, but also the
recently highlighted ‘early phase’ imaging. We focus on two key areas:
(a) the diagnostic utility of amyloid-PET in CAA, including a practical
algorithm based on the available evidence; and (b) the use of amyloid-
PET as a window to understand pathophysiological mechanisms of the
disease. Of note, all the PET studies in CAA published to date have used
amyloid PET tracers, i.e., no article on CAA using other PET tracers
such as FDG have appeared thus far. Where relevant, limitations and
gaps in the literature are highlighted, with recommendations for future
studies. Finally, our paper focusses on the more common and clinically
relevant at a larger scale sporadic CAA, rather than the rare hereditary
CAA syndromes (Greenberg et al., 2008) and hereditary systemic
transthyretin amyloidosis with CAA (Sekijima et al., 2016) for which
PET studies remain extremely limited.
2. Methods: search strategy and literature review
We searched PubMed from inception until September 1, 2016 using
a combination of keyword search and MeSH terms: (PET OR PiB OR
Pittsburgh OR positron emission tomography) AND (amyloid angio-
pathy). Reference lists from all included articles, review papers on the
topic and the authors' own ﬁles were also searched for relevant studies
in English. Two authors identiﬁed potentially relevant studies: (a) on
the diagnostic utility of amyloid PET in sporadic CAA (excluding case
reports and studies only including AD patients); (b) on potential
pathophysiological mechanism of brain injury in sporadic CAA; and
(c) other relevant studies on CAA. The ﬁnal list of references was
decided upon consensus between all co-authors, based on their
relevance to the themes covered in this review.
2.1. Data extraction
Two authors independently extracted data from all eligible studies
on comparison groups i.e., CAA, healthy controls (HC), AD, CAA
clinical presentation, imaging analysis method and main results. For
the CAA and HC groups, relevant data on PiB-PET amyloid positivity
were extracted if available, or calculated, and sensitivity and speciﬁcity
were derived from these data.
3. Results
Based on our search criteria, we identiﬁed 94 publications, of which
we retained 17 for the present study. Fig. 1 presents the ﬂow chart for
exclusion of studies.
3.1. Diagnostic utility of amyloid PET in sporadic CAA (Table 1)
3.1.1. Late amyloid brain uptake
3.1.1.1. CAA vs healthy controls (HCs). Four papers have provided data
comparing late amyloid uptake in CAA and HCs (Baron et al., 2014;
Gurol et al., 2012; Johnson et al., 2007; Ly et al., 2010a), although in
one study this was not the primary aim (Gurol et al., 2012). Of note,
HCs recruited into these studies had no cognitive complaint and had
normal MMS; only Gurol et al., 2013 did not report speciﬁcally on the
cognitive status of their HCs. Table 2 provides a summary. In total, the
data from 71 patients were reported (67 diagnosed as probable CAA, 4
as possible CAA), and of 87 age-matched HCs. Interestingly, Baron et al.
used 3T T2*-GRE MRI to assess the presence of microbleeds in the HCs
and excluded post-hoc one HC based on the presence of> 2 lobar
microbleeds, i.e., potentially due to asymptomatic CAA. Among
reported CAA patients, there were 48 lobar ICH cases and 27 with
non-ICH presentations (mainly seizures, cognitive complaints, subacute
encephalopathy). Two studies reported only CAA-lobar ICH patients
(Baron et al., 2014; Ly et al., 2010a), and the remaining two mixed-
presentations CAA samples.
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All four studies used PiB and fully quantitative analysis by kinetic
modelling of the whole time-activity curves to derive the distribution
volume ratio (DVR, using the cerebellum as reference tissue) as an
index of speciﬁc binding, using the values averaged across the whole
cortex. Three of them also used regional analysis and cortical regions of
interest (ROI) ratios (Johnson et al., 2007), Ly et al., 2010a, 2010b,
Baron et al., 2014). Of note, the brain regions aﬀected by previous
haemorrhages were consistently excluded from the analysis. Two
studies also used simple visual analysis of the brain uptake images
obtained in the late period after tracer injection (normalized to injected
dose and subject's weight, so-called standardized uptake values or SUV,
and divided by mean cerebellar SUV, generating SUVr images), (Baron
et al., 2014).
Using DVR, three studies reported signiﬁcantly higher cortical PiB
uptake in CAA patients in comparison with HCs (Gurol et al., 2012;
Johnson et al., 2007; Ly et al., 2010a), while one study found no
signiﬁcant diﬀerence (Baron et al., 2014).
Individual analysis comparing PiB positivity in CAA patients vs
controls was reported in three studies (Baron et al., 2014; Johnson
et al., 2007; Ly et al., 2010a). The reference diagnostic standard in all
analyses was CAA according to the Boston criteria (Table 1). Using
visual analysis, Johnson et al. (Johnson et al., 2007) found positive PIB
PET in all probable CAA patients, as well as in 6/15 aged-matched HCs.
Using the 75% percentile of the aged-matched HC group as cut-oﬀ, Ly
et al. (2010a) reported PiB positivity in 9/12 CAA patients (7/8
probable CAA and 2/4 possible CAA); by deﬁnition, 25% of the aged-
matched HCs were therefore PiB+. Using as DVR cut-oﬀ the 95% upper
conﬁdence limit from 10 young (< 55 years) HCs as control group to
account for the frequent positivity known to be present in older HCs,
Baron et al. (Baron et al., 2014) found 10/11 positive PIB in probable
CAA patients, and in 4/9 aged-matched HCs. Using visual analysis, the
values were 9/11 and 4/9, respectively, indicating lower sensitivity
than with the quantitative method.
Only one study (Baron et al., 2014) formally reported on sensitivity
and speciﬁcity of PiB-PET for CAA diagnosis. Based on the above data,
they reported a sensitivity of 91%, a speciﬁcity of 55%, a positive
predictive value of 71%, and a negative predictive value of 83%. As will
be addressed in the Discussion section, similar data can however be
calculated from two other studies based on reported raw data (Johnson
et al., 2007; Ly et al., 2010a).
Similarly, only one study (Baron et al., 2014) compared the regional
PiB uptake data (corrected for grey matter atrophy) between probable
CAA and aged-matched HCs, reporting no signiﬁcant diﬀerence for any
regional cortical DVR value between the two groups. Based on the
neuropathological evidence of more severe CAA pathology in the
posterior, and particularly occipital, cortical areas, this study also
assessed the occipital/whole cortex and frontal/whole cortex ratios,
and again found no signiﬁcant diﬀerence between the two comparison
groups.
3.1.1.2. Comparison between probable CAA-ICH and deep ICH. Two
studies used deep (presumably hypertensive, non-CAA) ICH as
controls to assess amyloid PET in lobar (presumably CAA-related)
ICH (Gurol et al., 2016; Raposo et al., 2014a, 2014b). See Table 1 for
details. Of note, the Raposo et al. (2014a, 2014b) study has been
published as an abstract only, and many important clinical details are
missing. In total, 28 lobar and 30 deep hypertension-related ICHs were
studied (Raposo et al., 2014a, 2014b). Of the lobar ICHs, Gurol et al.
(2016) and Raposo et al. (2014a, 2014b) studied 10 patients with
probable CAA each, and the latter authors also studied 4 patients with
possible CAA (note: 4 lobar ICH patients categorized as neither
probable nor possible CAA based on their abstract). Both studies used
Fig. 1. Flow chart of study identiﬁcation and selection.
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18F-ﬂobetapir, and both performed whole cortex SUVR analysis using
the cerebellum as reference. In addition, Gurol et al. performed regional
SUVR and DVR analyses, as well as visual analysis.
Both studies report signiﬁcantly higher whole cortex SUVR in lobar
vs deep ICH. Also, Raposo et al. (2014a, 2014b) found signiﬁcantly
higher amyloid burden in probable as compared to possible CAA lobar
ICH. Based on visual analysis, Gurol et al. (2016) found positive
amyloid PET in all 10 probable CAA patients, vs 1/9 deep ICH, i.e. a
sensitivity of 100% and a speciﬁcity of 89%. Raposo et al. (2014a,
2014b) did not report on individual visual classiﬁcation. Only Gurol
et al. (2016) reported on regional 18F-ﬂobetapir uptake. These authors
found a signiﬁcantly higher occipital/global uptake ratio in probable
CAA-related as compared to hypertension-related deep ICH.
3.1.1.3. Comparison between probable CAA and Alzheimer's disease
(AD). As will be extensively addressed in the Discussion section,
given the relatively high occurrence of amyloid PET positivity with
AD pattern in aged controls, one major issue regarding the diagnostic
utility of this approach in suspected CAA patients is whether a
signiﬁcant diﬀerence exists in the regional distribution pattern of
abnormal amyloid deposition as detected in vivo by PET (Baron
et al., 2014). To (overtly or covertly) address this issue, three articles,
all using PiB, have compared amyloid uptake in probable CAA vs
probable AD patients (Gurol et al., 2012; Johnson et al., 2007; Ly et al.,
2010a) (Table 2).
Two studies (Johnson et al., 2007; Ly et al., 2010a) found a
signiﬁcantly higher whole cortex PiB uptake (either DVR ort SUVR)
in AD than in CAA, while Gurol et al. (2013) reported no signiﬁcant
diﬀerence. Based on the notion that CAA is more severe in occipital
regions (Kovari et al., 2013; Vinters, 1987; Vinters and Gilbert, 1983),
which conversely are largely spared in AD, both groups compared the
occipital/whole cortex or neocortex uptake between the two patient
populations, predicting a higher ratio in CAA. Eﬀectively, both groups
found a signiﬁcantly higher occipital/whole cortex PIB ratio in CAA
than in AD patients for either DVR or SUVR. As a corollary, the frontal/
neocortical PiB uptake ratio was signiﬁcantly higher in AD than in CAA
patients in the Ly et al. (2010a).
Only Johnson et al. (2007) assessed the diagnostic value of PiB PET
in CAA vs AD. Using visual analysis, they found PiB positivity in 100%
of patients of either group. No study has reported on the diagnostic
value of regional uptake for diﬀerentiating CAA from AD, either using
quantitative ratios or visually.
As will be seen in the Discussion section, one study (Baron et al.,
2014) mentioned ﬁndings regarding the comparison of CAA vs AD as
ancillary data in their study comparing probable CAA patients to
healthy controls.
For illustration purposes, Fig. 2 presents typical PiB uptake images
in aged healthy controls, CAA and AD.
3.1.2. Early PiB uptake
One recent study reported on the use of early PiB uptake in CAA
(Farid et al., 2015). The underlying idea was based on the well-
established notion that early tracer entry in brain tissue reliably reﬂects
perfusion, which in turn could have diagnostic value in the study of
CAA. Importantly, in the resting state brain perfusion is highly
correlated with FDG uptake, and eﬀectively several studies have shown
that early PiB or 18F-ﬂobetapir uptake is indeed well correlated with
FDG uptake in healthy controls and AD, and can be used as a proxy of
brain energy metabolism (Forsberg et al., 2012; Rostomian et al., 2011;
Rodriguez-Vieitez et al., 2017). Thus, using both the early and late
tissue uptake of amyloid tracers could, from the same PET session,
provide information on both neurodegeneration/parenchymal and
cerebrovascular amyloid burden.
3.1.2.1. Probable CAA vs aged-matched healthy controls. Farid et al.
(2015) used the PET data from the 1–6 min frame after PiB
administration and generated atrophy-corrected SUVR images using
the cerebellar vermis as reference tissue, and compared 11 non-
demented patients with probable CAA-related lobar ICH to 9 aged-
matched HCs with normal MMSE (same population as in (Baron et al.,
2014)). Using regional quantitative analysis (excluding the areas of
previous haemorrhage), CAA patients had signiﬁcantly lower early-
phase PiB whole cortex uptake than HCs. Using as cut-oﬀ the 95% lower
conﬁdence limit from 10 young controls as detailed above (Baron et al.,
2014), none of the HCs had whole cortex early PiB uptake below this
cut-oﬀ whereas 6/11 CAA patients did. Thus, the sensitivity was 55%,
the speciﬁcity 100%, the predictive positive value was 100% and the
predictive negative value was 64% for CAA diagnosis using early PiB-
PET data.
3.1.2.2. Probable CAA vs AD. The same authors (Farid et al., 2015)
compared regional early PiB uptakes between probable CAA and AD.
Based on known pathological distribution of lesions in CAA (see above)
and pretesting state perfusion/FDG uptake in AD, they focused on the
occipital and posterior cingulate cortices. Consistent with these notions,
they found signiﬁcantly lower occipital early PiB uptake in CAA than
AD, but no signiﬁcant diﬀerence regarding the posterior cingulate area.
Consequently, the occipital/posterior cingulate ratio was signiﬁcantly
lower in CAA than in AD (Fig. 3). Sensitivity and speciﬁcity for this
ratio is not presented given the small AD sample used (n= 7).
Fig. 2. Typical PiB uptake images (one axial brain cut) in aged healthy controls (HC), probable CAA and AD. From left to right are shown examples of i) normal scan (i.e., PiB−) in an
aged HC; ii) positive PiB scan (i.e., PiB+) in another aged HC, adopting the typical ‘Alzheimer disease (AD)-like pattern’, namely uptake highest in frontal cortex; iii) PiB-probable
cerebral amyloid angiopathy (pCAA) subject; iv) PiB+ pCAA subject, AD-like pattern; v) PiB+ pCAA subject, with ‘CAA-like pattern’, namely equal uptake in occipital and frontal cortex;
and vi) PiB+ AD subject, AD-like pattern. Note that these images are shown only for illustrative purposes as signiﬁcant overlap exists between these typical patterns across clinical
entities (see Discussion).
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3.2. PET as a window to explore pathophysiological mechanisms in CAA
(Table 3)
3.2.1. Haemorrhagic manifestations
In a cross-sectional study of 16 patients with probable CAA,
signiﬁcantly higher PiB DVR was detected at sites of lobar microbleeds
as compared to other locations, suggesting that high local vascular
amyloid burden probably underlies vascular rupture causing micro-
bleeds (Dierksen et al., 2010). In a longitudinal study of 11 patients
with probable CAA, PiB retention at baseline was higher at regions-of-
interest (ROIs) that developed new lobar CMBs or ICH at> 1-year
follow-up MRI, providing further evidence that vascular amyloid
burden contributes to the occurrence of new lobar CMBs and ICHs
(Gurol et al., 2012). In a completely diﬀerent perspective, another study
(Ly et al., 2010b) reported higher PiB binding in patients with vs those
without post-thrombolysis parenchymal haemorrhage, but not for
diﬀerentiating simple haemorrhagic transformation, suggesting a role
for vascular amyloid burden in t-PA-related brain haemorrhage sus-
ceptibility. The location of the parenchymal hematoma, i.e. within or
remote from the ischemic area, was not detailed.
Ly et al. (2015) reported a case series of seven patients with non-
aneurysmal convexity subarachnoid haemorrhage (cSAH) fulﬁlling the
Boston criteria for probable CAA who all showed a positive PiB scan by
visual analysis, reinforcing the idea of a relationship between vascular
amyloid burden and cSAH. Dhollander et al. (2011) and Na et al. (2015)
investigated the relationship between PiB uptake and cortical super-
ﬁcial siderosis (cSS). The former reported a signiﬁcantly higher PiB
uptake in the immediate vicinity of cSS in two probable CAA patients,
while the latter found a close relationship between the presence of cSS
and PiB positivity in a large sample of patients with AD or subcortical
vascular cognitive impairment (SVCI), such that PiB was positive in
100% of the patients with cSS (n= 12) as compared to 57% of the
subjects without cSS. In other words, cSS was never present in PiB-
patients, supporting the idea that a vascular amyloid process underlies
cSS. Although application of the Boston criteria in the patients of this
study is not presented, it can be assumed that cSS was part of the
spectrum of CAA either in isolation or in association with AD pathology.
3.2.2. White matter changes
So far, only one study has addressed the relationship between
hemispheric white matter hyperintensities (also called leukoaraiosis)
and amyloid binding in probable CAA (Gurol et al., 2013). To test the
speciﬁcity of the association, these investigators also included non-CAA
cohorts where WMHs are also frequently encountered, namely aged
healthy controls and AD patients. This study found a strong correlation
between leukoaraiosis volume and global PiB DVR in probable CAA
patients, which was not present in healthy controls or AD, suggesting
that it is the vascular, not the parenchymal amyloid, that drives this
association. In other words, vascular amyloid aﬀecting the penetrating
cortical arterioles might directly cause chronic white matter ischemia
and hence leukoaraiosis.
A more recent study (Charidimou et al., 2015a) investigated the
relationship between enlarged perivascular spaces (PVS) in the cen-
trum-semi-ovale (CSO), a recently proposed new potential MR marker
of CAA, and PiB burden. They found a signiﬁcant relationship between
the number of CSO-PVS and whole cortex PiB DVR across both probable
CAA patients and elderly healthy controls, as well as within each group
separately. Importantly, no such relationship was observed for basal
ganglia PVS, which have been more closely associated with hyperten-
sive arteriopathy. These ﬁndings suggested that amyloid burden in the
penetrating cortical arterioles in some way might cause or contribute to
CSO-PVS across the aging and CAA spectrum (Charidimou et al.,
2015a).
3.2.3. Cognitive manifestations
In CAA, vascular amyloid leads to various types of brain damage,
including focal and more widespread parenchymal brain injury.
Accordingly, slowly progressive cognitive manifestations are frequently
associated with CAA. One subtype of cognitive presentation of CAA is
however subacute, in the form of an encephalopathy or rapidly
progressing dementia related to CAA-induced inﬂammation with
marked focal hemispheric white matter vasogenic edema and rapid
response to corticosteroids (Carmona-Iragui et al., 2016). Although the
ﬁnding of multiple lobar microbleeds is now part of the diagnostic
criteria (Linn et al., 2010), some patients still go on to have a brain
biopsy, with attending risks. A small case series study (Carmona-Iragui
et al., 2016) reported 4 patients with cognitive manifestations due to
CAA-related inﬂammation, two of which had a PiB scan over a year
after their episode. Both patients were PiB positive by visual assess-
ment, suggesting a potential usefulness of amyloid PET in the work-up
of these patients.
Using MR-based diﬀusion tensor imaging (DTI) a single center study
(Reijmer et al., 2015) assessed global network eﬃciency in a large
sample of probable CAA patients. As compared to aged healthy
controls, global network eﬃciency was signiﬁcantly reduced in CAA
patients and was related to MR-markers of CAA. In the subsample of
CAA patients who underwent a PiB scan, global network eﬃciency was
related to higher cortical PiB DVR, including an association with the
regional distribution of the two measures, i.e., more posterior amyloid
burden related to more posterior network disruption, suggesting that
network eﬃciency partly mediates the relationship between vascular
amyloid burden and cognitive impairment.
4. Discussion
4.1. Diagnostic value
The ultimate aim of in vivo non-invasive diagnostic tests in CAA is
to replace the need of brain biopsy/autopsy to make a deﬁnite formal
diagnosis of CAA. This would have clinical impact in ‘probable CAA’
according to the Boston criteria, which has very good but imperfect
diagnostic accuracy, but especially for the ‘possible CAA’ category, as
detailed in the Introduction.
4.1.1. Summary of main ﬁndings: whole-cortex tracer uptake
Six publications have addressed (or reported data useful to address)
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Fig. 3. Early-phase PiB Occipital/Posterior cingulate cortex uptake ratio in probable CAA
and AD. The diﬀerence in ratio between the two groups is highly signiﬁcant (p= 0.002;
Mann-Whiney test). This graph shows the presence of a substantial though limited
overlap between the two populations, with a ratio around one discriminating all AD
subjects vs 9/11 CAA subjects. See Methods and (Farid et al., 2015) for details.
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the diagnostic utility of late-phase amyloid PET imaging in CAA, and
one additional study dealt with early PiB images as a proxy of brain
perfusion (Table 2). Out of these, four have provided data comparing
late amyloid uptake in CAA to HCs, and all used PiB (Baron et al., 2014;
Gurol et al., 2012; Johnson et al., 2007; Ly et al., 2010a). Three
reported a signiﬁcantly higher whole-cortex PiB uptake in CAA relative
to age-matched HCs (Gurol et al., 2012; Johnson et al., 2007; Ly et al.,
2010a), while no signiﬁcant diﬀerence was found in one (Baron et al.,
2014).
Three studies report the number of subjects with positive or
negative PiB scan (Baron et al., 2014; Johnson et al., 2007; Ly et al.,
2010a). The reported PiB positivity in probable CAA was 10/11, 6/6
and 7/8, respectively, with corresponding data in HCs of 4/9, 6/15 and
75% (of 22 subjects, i.e., 5 or 6), respectively. Thus, the vast majority
(23/25; 92%) of probable CAA patients were PiB+, indicating an
excellent sensitivity. In other words, a negative PiB scan rules out CAA
with very high conﬁdence. However, speciﬁcity was found to be
suboptimal due to the frequent occurrence of high PiB uptake in the
aged-matched HCs (15 or 16/46, i.e., 1/3), despite normal general
cognition (Table 1). This translates into a speciﬁcity of ~66%. This
incidence of PiB+ in cognitively normal elderly subjects is entirely
consistent with the literature and is thought to reﬂect incipient
Alzheimer's disease (Mintun et al., 2006; Rowe et al., 2013). One study
only (Ly et al., 2010a) reported PiB data in possible CAA (n= 4), with 2
being positive (50%), but without conﬁrmation from a brain biopsy it is
uncertain if these patients did have CAA.
A caveat regarding sensitivity for CAA diagnosis is that in patients
with suspected CAA, PiB positivity might be incidental, given that the
incidence of asymptomatic CAA at autopsy in healthy aged subjects is
up to 50% (Kovari et al., 2013). Likewise, due to the frequent co-
occurrence of both CAA and AD (Ducharme et al., 2013), patients
suspected of CAA might have associated incipient AD accounting for
PiB positivity, while conversely healthy controls might harbor incipient
CAA. This is particularly important, given the inadequate speciﬁcity of
amyloid PET. PiB and other amyloid tracers are non-speciﬁc imaging
markers of Aβ peptide-related parenchymal or cerebrovascular amyloid
deposition. Thus, diﬀerentiating PiB signal caused by CAA from that
caused by other kinds of amyloid deposits is impossible (Klunk et al.,
2004; Klunk et al., 2003).
CAA and AD share common molecular mechanisms and certain
neuropathological features, but they remain indistinct disease entities,
especially when presenting with their sentinel clinical phenotypes.
While in AD, CAA can be found in the majority of cases if looked for
meticulously, it is usually mild to moderate (Vinters, 2015). By
contrast, in CAA with lobar ICH, a well-deﬁned symptomatic phenotype
of the disease, especially relevant for amyloid PET studies reviewed
here, CAA pathology is severe (usually stage 2 or higher in the Vonsattel
scale) (Greenberg and Vonsattel, 1997). In turn, for a deﬁnitive
neuropathological diagnosis of CAA to be made, a full autopsy is
required, typically demonstrating moderate-to-severe cerebrovascular
amyloid deposition (Vonsattel stage 2 or more). This is diﬀerent to “any
degree” of vascular amyloid, mainly including mild CAA, which is
commonly found to accompany amyloid plaques in AD brains. A recent
MRI-neuropathological study compared patients with pathologically
proven CAA presenting clinically with or without ICH (Charidimou
et al., 2015c).> 90% of pathology samples in both groups had neuritic
plaques, whereas neuroﬁbrillary tangles (a hallmark AD lesion) were
more commonly present in the patients without ICH (87% vs 42%,
p < 0.0001) (Charidimou et al., 2015c). Detailed neuropathological
information on the Thal and Braak's stages according to age, were not
available in this study. In most CAA cases presenting with ICH, the
severity degree for amyloid plaques and tangles necessary for a
neuropathological diagnosis of AD is not typically met (Hyman et al.,
2012). It is important to highlight that amyloid plaques are extremely
frequent neuropathologically even in cognitively normal people
(around 50% in those> 75 years) (Thal et al., 2002), and thus elderly
patients with pure CAA presentations are expected to harbor some
amyloid plaques in this context. A large proportion of patients might be
situated between these two ends of the amyloid pathologies spectrum.
This probably causes some degree of overlap in amyloid PET appear-
ance, yet severe degrees of amyloid deposition aﬀects a fewer propor-
tion of normal people, similar to the case in CAA. Hence, the attempt to
diﬀerentiate CAA from AD using amyloid PET could be challenging and
needs to be based on a number of measures. These include ratios, early
PiB update and tau (see below), attempting to dissect out a CAA pattern
even on this background of AD-type amyloid deposition and distribu-
tion.
Another important aspect that deserves consideration is the role of
APOE alleles. APOE ε4 is a known risk factor for AD pathology
(Verghese et al., 2011), is associated with a higher likelihood of a
positive amyloid PET scan in this setting, as well as with a higher
likelihood of lobar microbleeds on blood-sensitive MRI. The role of
APOE ε4 has also become more evident by the higher risk of ARIA in
immunotherapeutic clinical trials of AD patients. APOE genotype is also
among the key genetic determinants of CAA (Greenberg et al., 1996;
Greenberg et al., 1995). APOE ε4 enhances cerebrovascular amyloid-β
deposition in a dose-dependent manner (Rannikmae et al., 2013). It is
hypothesized that APOE ε2 promotes vasculopathic changes (vessel
cracking, vessel-within-vessel appearance and ﬁbrinoid necrosis-the
most severe stage of CAA) which can in turn result to vessel rupture
(Greenberg et al., 1998) including lobar ICH (Charidimou et al., 2015c;
Martinez-Ramirez et al., 2014). However, there are no relevant data on
how could APOE aﬀect amyloid PET imaging in CAA patients, and this
as an area for future investigation. In a memory clinic study, cortical
superﬁcial siderosis (a major haemorrhagic CAA biomarker) was
associated with other markers of CAA severity, and higher cortical
PET-based retention, as well as APOE ε2 presence (Na et al., 2015).
How APO-E polymorphism aﬀects amyloid PET in CAA is an important
area for future work.
Two additional studies, both using 18F-ﬂorbetapir, are relevant to
the diagnostic potential of amyloid PET in CAA (Gurol et al., 2016;
Raposo et al., 2014a, 2014b). They both compared patients with
probable or possible CAA-related symptomatic lobar ICH to patients
with symptomatic deep ICH (related to hypertension in Gurol et al.; not
stated in Raposo et al) as controls. Both studies found signiﬁcantly
higher global tracer uptake in lobar vs deep ICH, with in addition
probable CAA having signiﬁcantly higher uptake than possible CAA
(Raposo et al., 2014a, 2014b). Of note, this diﬀerence in tracer uptake
between the two groups was present even though 70% of the probable
CAA patients were hypertensive, pointing to CAA per se as causing the
diﬀerence (Gurol et al., 2016). Only Gurol et al. (2016) assessed
individual PET positivity (using visual analysis), and reported 10/10
(100%) positivity in lobar ICH vs 1/9 (11%) in deep ICH. These ﬁndings
are consistent with the excellent sensitivity of PiB relative to HCs
detailed above. However, the speciﬁcity reported in this study (Gurol
et al., 2016) is much higher than previously reported using HCs (see
above), yet it would intuitively be expected that elderly subjects with
hypertension-related ICH would have similar incidence of incipient AD
than HCs. This might be related to the fact that the patients studied in
this cohort (Gurol et al., 2016) had a mean age of 67 years, i.e.,
relatively young. Individual patient analysis is not reported in Raposo
et al.'s published abstract (Raposo et al., 2014a, 2014b).
4.1.2. Summary of main ﬁndings: regional tracer uptake
As just addressed, the poor speciﬁcity of whole-cortex amyloid
tracer uptake vs healthy controls aﬀects the diagnostic utility of
amyloid PET imaging in CAA. However, if the regional PiB uptake
pattern diﬀered between AD and CAA, it might be possible to
distinguish these two causes of PiB positivity as a subsequent step in
the diagnostic workﬂow. In other words, in case of PiB positivity
relative to HCs, the next step would be to compare the uptake pattern to
that present in AD (Fig. 4). As explained in the Results section, all
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studies so far have focused on the frontal vs occipital contrast. The
ﬁndings across studies regarding the comparison of the occipital/
global, frontal/global and occipital/frontal uptake ratios between
probable CAA and HCs or AD samples are summarized in Table 4. As
this table shows, only disparate results have been reported so far,
precluding any deﬁnitive conclusion.
Only Baron et al. (2014) have compared ratios in CAA vs age-
matched HCs, reporting no signiﬁcant diﬀerence. However, comparing
CAA-related ICH patients to hypertension-related deep ICH subjects,
Gurol et al. found a signiﬁcantly higher occipital/global tracer uptake
in CAA (Gurol et al., 2016); the frontal ratio did not signiﬁcantly diﬀer
between the two groups.
Two studies have reported comparison in probable CAA vs probable
AD (Johnson et al., 2007; Ly et al., 2010a). In both studies the
occipital/whole cortex ratio was signiﬁcantly lower, and in Ly et al.
(2010a) the frontal/whole cortex ratio signiﬁcantly higher, in AD than
CAA. Consistent with the above results, Baron et al. (2014) mentioned
in their discussion section a signiﬁcantly higher calcarine/frontal cortex
ratio in CAA as compared to a small sample of AD patients (n= 7).
Although this ﬁnding of an inverted occipital/frontal gradient of
amyloid uptake between CAA and AD is important to highlight,
especially as it is consistent with the known neuropathological burden
in CAA (see above), the data shown in Johnson et al. (2007) and Ly
et al. (2010a) (Fig. 3 in both articles) suggest some overlap is present
between the two groups, in turn potentially hindering clinical utility.
Interestingly, Baron et al. (2014) presented a visual analysis of their PiB
+ CAA patients according to an ‘AD’ or ‘non-AD’ proﬁle, essentially
based on occipital cortex uptake, and report 2/3rds of non-AD proﬁle,
consistent with the above quantitative data. Relevant to this discussion
Fig. 4. Diagnostic ﬂow chart algorithm of possible amyloid-PET use in the clinical setting of suspected CAA, based on currently available evidence presented in this review article. This
stepwise algorithm is based on three successive steps: i) late-phase amyloid PiB-PET is compared to young controls; ii) if PiB+, then the regional pattern is compared to AD; iii) if still
unclear, then the pattern of early PiB images are compared to AD. Note this is a tentative work-ﬂow that is not to be used as evidence-based for routine clinical practice but meant to serve
as starting point for future studies.
Table 4
Summary of ﬁndings regarding occipital and frontal regional assessment of late-phase
amyloid tracer brain uptake.
Occipital/global ratio Frontal/global
ratio
Occipital/frontal
ratio
CAA vs
HCs
NS (Baron et al., 2014) NS (Baron et al.,
2014)
N/A
CAA vs
HTN-
ICH
CAA > HTN-ICH
(Gurol et al., 2016)
NS (Gurol et al.,
2016)
N/A
CAA vs AD CAA > AD (Johnson
et al., 2007; Ly et al.,
2010a)
CAA < AD (Ly
et al., 2010a)
CAA > AD (Baron
et al., 2014)
CAA: cerebral amyloid angiopathy; HC: healthy controls; NS: no statistically signiﬁcant
diﬀerence;> or< : signiﬁcantly larger or smaller; HTN-ICH: arterial hypertension-
related intracerebral haemorrhage; AD: Alzheimer's disease; N/A: not available.
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is a single-case report with post-mortem assessment of an elderly
patient diagnosed in life with probable AD-related cognitive impair-
ment (MMSE = 23) and positive PiB PET with typical regional pattern
(i.e., frontal predominance with low occipital uptake), whose patholo-
gical diagnosis was CAA without Alzheimer hallmarks (Ducharme et al.,
2013). Interestingly, T2-weighted MRI in this patient showed extensive
posterior white matter hyperintensities and CSO-PVS, which could have
raised the diagnosis of CAA, but T2* imaging was not performed.
Unfortunately, one of the larger PiB-PET studies in CAA (Gurol et al.,
2013) did not present data on posterior predominance of amyloid tracer
retention level in CAA, which would have been useful for further testing
this hypothesis. Overall, therefore, the expected diﬀerence in anterior/
posterior amyloid tracer uptake gradient between CAA and AD is
deﬁnitely present, however it is unclear whether it has diagnostic
signiﬁcance given the apparent substantial data overlap between the
two clinical entities, mirroring the above discussion on neuropatholo-
gical overlap. Further studies on larger samples directly testing the
clinical utility of ratios are warranted at this stage.
To aid the diﬀerential diagnosis of CAA vs AD, and based on
premises detailed in Methods, a recent study (Farid et al., 2015)
assessed the potential use of early PiB images (1–6 min uptake) as a
surrogate of resting-state perfusion/metabolism. They predicted that
AD and CAA diﬀer in early PiB pattern, with lower occipital and higher
posterior cingulate cortex (PCC) uptake in CAA than AD. Consistent
with this hypothesis, they report a signiﬁcantly lower occipital/PCC
ratio in CAA than AD. However, there was still some overlap in
individual data (Fig. 4). Interestingly, early PiB occipital cortex uptake
was signiﬁcantly lower in CAA patients as compared to HCs, consistent
with a recent article reporting a strong trend for reduced MR-based ASL
perfusion in the occipital cortex in hereditary CAA with previous lobar
ICH (van Opstal et al., 2017). These data suggest that by detecting
perfusion-like abnormalities, early-phase PiB-PET might add diagnostic
value in combination to late-phase PiB-PET, and particularly help
diﬀerentiate CAA from Alzheimer's disease. By extension, brain perfu-
sion or metabolism (e.g., FDG PET) imaging using the occipital/PCC
ratio might help to clarify the CAA vs AD ambiguity in case of late-
phase PiB positivity. Further studies in larger cohorts are needed to
ascertain this.
Two additional studies, both using 18F-ﬂorbetapir, are relevant to
the diagnostic potential of amyloid PET in CAA (Gurol et al., 2016;
Raposo et al., 2014a, 2014b). They both compared patients with
probable or possible CAA-related symptomatic lobar ICH to patients
with symptomatic deep ICH (related to hypertension in Gurol et al.; not
stated in Raposo et al.) as controls. Both studies found signiﬁcantly
higher global tracer uptake in lobar vs deep ICH, particularly so in the
occipital cortex (Gurol et al., 2016), with probable CAA having
signiﬁcantly higher uptake than possible CAA (Raposo et al., 2014a,
2014b). Of note, this diﬀerence in tracer uptake between the two
groups was present even though 70% of the probable CAA patients were
hypertensive, pointing to CAA per se as causing the diﬀerence (Gurol
et al., 2016). Only one study (Gurol et al., 2016) assessed individual
PET positivity (using visual analysis), and reported 10/10 (100%)
positivity in lobar ICH vs 1/9 (11%) in deep ICH. These ﬁndings are
consistent with the excellent sensitivity of PiB relative to HCs detailed
above. However, the speciﬁcity reported in this study (Gurol et al.,
2016) is much higher than previously reported using HCs, yet it would
intuitively be expected that elderly subjects with hypertension-related
ICH would have similar incidence of incipient AD than HCs. This might
be related to the fact that the patients studied in this cohort (Gurol
et al., 2016) had a mean age of 67 years., i.e., relatively young.
Individual patient analysis is not reported in Raposo et al.'s published
abstract (Raposo et al., 2014a, 2014b).
4.1.3. Methodological issues
The main issue pertains to how to classify subjects as amyloid PET
positive or negative. Out of the above six studies, two only used
quantitative cut-oﬀs towards objective categorization (Baron et al.,
2014; Ly et al., 2010a), and two visual classiﬁcation only (Gurol et al.,
2016; Johnson et al., 2007). One study reports the use of both methods,
showing a slight loss of sensitivity with the visual analysis (Baron et al.,
2014). The visual method is widely used in clinical practice. However,
this binary method of assessment requires a good inter-observer
reproducibility and has been described to have worse performance
than the quantitative one. In addition, visual analysis doesn't usually
assess the regional pattern (e.g., posterior vs anterior predominance), as
this would appear even less reliable.
Although the quantitative method is more robust and objective, the
whole-cortex tracer uptake threshold approach used to classify a subject
as positive or negative raises speciﬁc issues. Traditionally calculated
cut-oﬀs derived from SUVr are diﬀerent from, and higher than, those
derived from kinetic modelling of the entire time-activity curves since
injection time, so-called distribution volume ratios (DVRs) (~1.40 vs
~1.20, respectively). However, the statistical ways to derive them from
a control sample (Villeneuve et al., 2015) and the nature of the most
appropriate control sample (Baron et al., 2014), have been subject of
debate. For instance, if the control sample is small and/or has skewed
distribution, deriving a 95% conﬁdence limit might be inadequate. The
issue of the nature of the control sample is even more subject to
controversy. Thus, if aged-matched HCs are used to determine the cut-
oﬀ, the inevitable presence of a fraction of PET+ subjects will tend to
overestimate the cut-oﬀ and in turn, to classify truly positive patients as
negative. To circumvent this issue, Baron et al. (2014) used a sample of
young (< 55 years of age) HC sample, of whom none was visually PiB
+ as expected from the literature that shows that below this age
essentially no HC is PiB+ (Mintun et al., 2006; Rodrigue et al., 2012;
Vlassenko et al., 2016), consistent with post-mortem data (Thal et al.,
2002). Although the eﬀect of age < 55 years on PiB uptake is at best
extremely small (Rodrigue et al., 2012), other groups studying AD have
used even younger samples (20–30 years old), reporting a 95% UL of
1.07 for DVR (Mormino et al., 2012). Using older control samples, other
approaches than the 95% CL that take into account the presence of PiB
+ subjects use for instance non-parametric iterative outlier exclusion
approaches or gaussian mixture (two mixed gaussians) (Villeneuve
et al., 2015). A PiB study in healthy subjects using post-mortem as gold-
standard found that traditional cut-oﬀs are too conservative, i.e. they
classify as negative subjects who are positive at post-mortem
(Villeneuve et al., 2015). These authors found that statistical methods
that produce less stringent cutoﬀs provided better concordance with
post-mortem than standard 95% CL, and advocated cut-oﬀs of 1.20 and
1.08 for SUVr and DVR, respectively. However, their sub-set of subjects
who had both PiB PET and post-mortem had a delay of three years
between the two, which might have biased the determination of
optimal cut-oﬀs. Regardless, the very concept of a rigid quantitative
cut-oﬀ is puzzling, and for instance Baron et al. (2014) indicated that
the only PiB-probable CAA patient in their sample had a whole cortex
PiB DVR of 1.20, just below the cut-oﬀ of 1.22, yet was considered
‘negative’ for the sake of scientiﬁc rigor. The same comments apply to
quantitative regional values or region-to-global or region-to-region
ratios.
Although the regional distribution of vascular amyloid burden in
CAA is well described, one study only has so far looked at the regional
late uptake values (Baron et al., 2014) as the focus has been on whole
cortex average uptake and less so on region/whole cortex or region/
region ratios (see above). Yet, it is feasible that focusing on brain
regions more likely to be aﬀected in CAA the diagnostic yield of
amyloid PET might improve further. However, the way to choose the
best combination of brain regions is unclear. Highly sensitive voxel-
based approaches such as those developed for FDG PET in AD (Herholz
et al., 2002) would be worth exploring. In addition, all studies but one
have chosen cerebellar cortex as a reference region (vs pons or
cerebellar vermis). Using the cerebellum as reference tissue relies on
the assumption that it has only non-speciﬁc binding at equilibrium.
K. Farid et al. NeuroImage: Clinical 15 (2017) 247–263
257
Although the cerebellum could be aﬀected by amyloid deposits as part
of CAA, it is not entirely clear how often, and to what degree CAA aﬀect
the cerebellum, and in all likelihood cerebellar involvement in not very
common and might only occur in late and severe stages of the disease
(Kovari et al., 2013). Because the cerebellar cortex might be aﬀected by
crossed cerebellar diaschisis (Baron et al., 1981), which causes a
reduction in perfusion, it is important to consider this possibility in
studies of early amyloid tracer uptake. Given that in CAA supra-
tentorial lesions are often bilateral, use of the cerebellar cortex may
aﬀect measurements normalized by cerebellum. Accordingly, in Farid
et al.'s study of early PiB uptake in CAA, the cerebellar vermis was used
as reference tissue (Farid et al., 2015).
Correction for the substantial partial volume eﬀect resulting from
the relatively poor spatial resolution of PET is another potential caveat
when deriving amyloid cortical tracer uptake values. This is because
cortical atrophy, which is present in CAA (Fotiadis et al., 2016),
artefactually reduces tracer uptake values in cortical ROIs because of
‘spill-out’ of radioactivity counts into CSF spaces (Quarantelli et al.,
2004). In turn this would result in artiﬁcially low tracer uptake values
and underestimated true amyloid binding. Although this issue is
probably more limited in CAA than in AD, where cortical atrophy is
major, it is probably not negligible. So far, only one study (Baron et al.,
2014) corrected PiB uptake data for presence of CSF in the cortical
ROIs. However, a comparison of the corrected and uncorrected data is
not presented.
Although intuitively minimal, the eﬀects of lobar haemorrhage on
amyloid tracer retention are unknown. However, no clear diﬀerence in
late-phase PiB uptake between probable CAA patients with and without
history of lobar ICH was mentioned in the two studies that included
both types of patients (Gurol et al., 2013; Johnson et al., 2007).
Generally, brain regions with previous ICH were removed from the ROI
analysis in all studies published in full so far (Table 2). Interestingly,
Farid et al. (2015) reported that the signiﬁcant reduction in early-phase
PiB uptake present in CAA as compared to aged-matched HCs became
insigniﬁcant if data from the hemispheres with previous lobar ICH were
removed from the analysis, an eﬀect they attributed to classic remote
perfusional/metabolic eﬀects of focal brain lesions, i.e. diaschisis
(Baron, 1989; Feeney and Baron, 1986). Nevertheless, this did not
aﬀect the diﬀerence in occipital/PCC ratio between the CAA and AD
groups, which remained highly signiﬁcant (Farid et al., 2015). Of note,
in the previously mentioned ASL perfusion study in hereditary CAA
(van Opstal et al., 2017), the areas of previous ICH were discarded from
the analysis, and the diﬀerence in occipital perfusion between patients
and controls was not quite signiﬁcant after correction for multiple tests;
the asymptomatic mutation carriers showed not even a trend for a
diﬀerence with controls.
4.1.4. Additional points
Heterogeneity in case-mix between the six diagnostic studies
reported so far needs mentioning (Table 1). Thus, in two studies
(Gurol et al., 2013; Johnson et al., 2007), the CAA sample reported
included essentially equal numbers of patients with lobar ICH and other
presentations (e.g., seizures, gait problems). Whether this might have
biased the ﬁndings is unclear insofar as no formal comparison of PiB
data between these patient categories is presented in either article.
Another key issue regarding the diagnostic potential of amyloid PET
in CAA is that essentially only probable CAA patients have been
reported so far. Two studies did include a few patients (8 patients in
total) with possible CAA-related lobar ICH (Ly et al., 2010a; Raposo
et al., 2014a, 2014b). In one, the two categories were merged for group
analyses, which may be problematic, but kept separate when assessing
PiB positivity, with 7/8 probable cases being PiB+ as compared to 2/4
possible CAA (Ly et al., 2010a). In the other study (Raposo et al., 2014a,
2014b), the probable CAA subgroup (n= 10) had higher ﬂorbetapir
uptake than the possible CAA subgroup (but n= 4 only). These limited
data would suggest lower amyloid binding in possible CAA, or alter-
natively that some possible CAA patients in fact did not harbor CAA.
Amyloid PET studies in possible CAA are eagerly awaited to assess the
potential diagnostic value of amyloid PET at this stage, where formal
diagnosis using molecular imaging would be even more useful than in
probable CAA. However, in order to allow proper interpretation of the
PET ﬁndings, prospective long-term follow-up will be necessary to
conﬁrm, or disprove, the diagnosis of CAA based on subsequent clinical
and imaging events. More generally, the lack of longitudinal amyloid
PET studies in CAA so far precludes making any hypothesis regarding
the time course of brain amyloid uptake in CAA, speciﬁcally how long
before the ﬁrst clinical presentation the amyloid scan becomes positive.
In other words, is - as suggested by a recent CSF study (van Etten et al.,
2017) - the situation in CAA similar to AD where it is estimated that
around 20 years elapse between signiﬁcant ﬁbrillar amyloid deposition
and ﬁrst symptoms, and where amyloid PET uptake essentially plateaus
after the ﬁrst symptoms surface (Jack et al., 2013; Villemagne et al.,
2013), or conversely that in CAA amyloid deposition occurs very soon
before, and continues to increase over time after, ﬁrst symptoms?
Studies in symptomatic vs asymptomatic mutation carriers in heredi-
tary CAA, on the model of similar studies in hereditary AD (Bateman
et al., 2012), should also provide key data regarding these issues.
Finally, a clinically relevant scenario, though relatively rare, is the
occurrence of suspected CAA in amyloid-positive patients below the age
of 55 (i.e., the lower age limit prescribed by the Boston criteria, see
Table 1) in the absence of known gene mutations. No study that far
focused on this population.
Two diﬀerent amyloid PET tracers, namely 11C-PiB and 18F-ﬂorbe-
tapir, have so far been used in diagnostic studies in CAA (Table 2).
Given that the latter has been validated post-mortem for selective
ﬁbrillar Aβ binding and in vivo against the former (Johnson et al.,
2007), they should provide similar information, and in turn sensitivity
and speciﬁcity. The advantage of 18F-ﬂorbetapir over 11C-PiB is that
thanks to the 2-h half-life of 18F as compared to 20 min for 11C, it is
already available commercially (although not yet reimbursed in many
countries) so would be used in clinical routine, were amyloid PET to
eventually prove its diagnostic utility.
A further point relates to the potential diagnostic value of amyloid
PET vs CSF assessment of Aβ 40 vs 42 (and relative to phosphorylated
and total tau content) (Piazza et al., 2013; van Etten et al., 2017). For
instance, amyloid PET might have added diagnostic value over and
above CSF, or vice-versa, or neither. No study on this is available to
date, however. The same comment applies to even more understudied
potential biomarkers of CAA such CSF Aβ antibodies.
4.2. Mechanistic studies
Because amyloid PET is the only method to date that provides in
vivo insight into the regional/local brain density of ﬁbrillar Aβ
deposition (as opposed to e.g., CSF which provides a single, indirect
global value only), it has the unique potential to decipher the
mechanisms involved in the various clinical and radiological features
of CAA, more precisely the role of local distribution, intensity and/or
pattern of cerebrovascular amyloid deposition in determining these
features. This in turn opens new avenues for proper application of
future therapies, and for directly monitoring the latter's eﬀects (Sevigny
et al., 2016). In practice, using amyloid PET imaging one can rigorously
and directly test pre-speciﬁed hypotheses on both the quantitative and
spatial associations of various indirect markers of CAA-related brain
injury with vascular Aβ burden. However, only limited studies have
been reported to date, typically with small sample sizes of selected
patient populations and with a variety of aims.
Regarding key haemorrhagic markers of CAA, two studies focused on
lobar CMBs and ICH (Dierksen et al., 2010; Gurol et al., 2012),
demonstrating with elegant techniques the spatial correlation between
CMBs and PET-based amyloid deposition in shells cross-sectionally, and
in areas of new bleeding. These ﬁndings suggested that lobar MBs and
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ICHs tend to occur in areas with particularly high vascular amyloid
burden, via vascular wall fragility. However, some caution is warranted
when interpreting these ﬁndings. A key limitation is the relatively poor
spatial resolution of PET (several mms) compared to MRI-detected
CMBs, introducing imprecision in the colocalisation ﬁndings. This
factor is even more pronounced if the actual neuropathological size of
CMBs is considered, being in general 5–20 times smaller than the
ﬁndings on MRI due to the ‘blooming eﬀect’ of the susceptibility
sequences (Shoamanesh et al., 2011). Quite intriguingly, however, a
recent ex vivo 7T MRI-neuropathological study found reduced vascular
amyloid burden at sites surrounding CMBs (vs control areas) in CAA
brains (van Veluw et al., 2017). The data reviewed here, overall support
the expected role of PiB retention as a measure of CAA burden in
producing brain injury, but do not inform the actual pathological
process leading to blood leaks. Secondly, the CAA cases recruited into
these PET studies mainly included cases with relatively large CMBs
counts (often> 15) (Dierksen et al., 2010; Gurol et al., 2012),
reﬂecting selection bias. Thus, the relevance of these ﬁndings in CAA
patients with few lobar CMBs remains unclear and requires replication
in larger studies. A potential general implication of the results might be
the possibility of preventing or reducing vascular amyloid as a measure
to lower the risk of future CAA-related bleeding or other brain injury.
This hypothesis has not been directly tested in anti-amyloid immu-
notherapy CAA trials.
Cortical superﬁcial siderosis (cSS) is emerging as another, and a
major, haemorrhagic signature of CAA and the most important
predictor of future lobar ICH occurrence, over and above CMBs
(Charidimou et al., 2015b). However, cSS has received little attention
in PET studies to date. The only available data come from two very
small case series (Dhollander et al., 2011; Ly et al., 2015) conﬁrming
the role of cSS as a marker of underlying CAA (see Results and Table 3).
A study in memory clinic patients (Na et al., 2015), provides the most
comprehensive data to date on cSS relationship to amyloid PET
imaging. A total of 232 patients with Alzheimer disease–related
cognitive impairment and 90 patients with SVCI were rated. cSS was
only found in 12 cases (equality distributed in the 2 diagnostic
categories), all with positive PET scans, and was associated with
indirect biomarkers of CAA presence: higher global PiB retention ratio
(relative to patients without cSS), APOE e2 allele, and a strictly lobar
microbleeds distribution in multivariate logistic regression analysis (Na
et al., 2015). It is important to keep in mind that this memory clinic
population, all with cognitive impairment, is not a typical ‘pure’
symptomatic CAA cohort, hence the generalizability of the results is
limited. However, and despite the very small sample size and the high
likelihood of amyloid PET burden reﬂecting AD-type neurodegenera-
tion, the results support the generally accepted notion of cSS being an
imaging manifestation of advanced CAA pathology. A well-designed
PET-MRI study in a probable CAA clinical population from stroke
clinics is needed to further explore the mechanisms of this promising
marker, including the global and focal association with amyloid
accumulation.
Almost equally as important are the white matter changes that occur
in CAA, namely white matter hyperintensities on T2/FLAIR MRI (and
appearing as leukoaraiosis on pklain CT) and the dilated perivascular
space in CSO, as both contribute to the cognitive deterioration, as well
probably to the gait impairment, that almost universally develop in
CAA survivors over time. In the same vein is the reported association in
a single study of white matter hyperintensities and PiB-PET in CAA
patients (Gurol et al., 2013), which included 42 non-demented CAA
patients, 50 healthy elderly participants and 43 AD/MCI patients. The
main pathophysiological argument in the paper is that vascular amyloid
burden as captured on PET directly contributes to chronic cerebral
ischemia, ultimately giving rise to leukoaraiosis. This interpretation is
largely based on the signiﬁcant correlation found between global PiB
retention and leukoaraiosis (rho = 0.52, p < 0.001) in the CAA group,
but not in the other two control groups. Since this was a cross-sectional
study, the CAA group included a mixture of ICH and non-ICH
presentations, and measures of cerebral blood ﬂow were not available,
it provides only weak support for the underlying hypothesis and
mechanistic interpretation. It does however provide evidence for an
overall association between total leukoaraiosis burden, a known marker
of small vessel disease with heterogeneous pathological basis, and
global PET-based amyloid in CAA (as a measure of SVD severity under
consideration). More detailed studies are needed to further dissect the
regional association between amyloid PET and patterns of leukoaraiosis
(e.g. occipital predominance and multiple spots in the white matter),
voxel based analysis of cortical amyloid-PET binding and subcortical
leukoaraiosis severity, as well as longitudinal analysis over time to
prove a causal link between the two measures. In this study, lobar CMBs
burden (note: the median CMBs count was 25, somewhat high
compared to other CAA cohorts), another putative marker of CAA
was also independently associated with leukoaraiosis volume, but other
key markers of CAA were not reported, such as cSS and perivascular
spaces which could modify the associations under investigation.
MRI-visible PVS in the cerebral white matter, particularly in the
CSO, is the latest addition as a neuroimaging CAA signature in the
appropriate clinical context (Charidimou et al., 2014; Charidimou et al.,
2013b; Martinez-Ramirez et al., 2013; Roher et al., 2003; van Veluw
et al., 2016). PVS (also termed Virchow–Robin spaces) are interstitial
ﬂuid-ﬁlled cavities surrounding small perforating arteries (Ozturk and
Aydingoz, 2002) forming potential perivascular channels conceptua-
lized as part of the brain drainage system for interstitial ﬂuid and
solutes, including soluble amyloid-β (Carare et al., 2008; Marin-Padilla
and Knopman, 2011). It is hypothesized that perivascular spaces are
pathologically enlarged when they start to appear on structural MRI,
but mechanisms for this assumption remain poorly understood. It is
important to clarify that there are no size criteria when perivascular
spaces are considered enlarged (see STandards for ReportIng Vascular
changes on nEuroimaging (STRIVE)) (Wardlaw et al., 2013). These
spaces follow the typical course of penetrating vessels as they go
through grey or white matter and hence they appear linear when
imaged parallel to the course of the vessel, and round or ovoid, with a
diameter generally smaller than 3 mm, when imaged perpendicular to
the course of the vessel (Wardlaw et al., 2013).
The association between MRI-visible PVS and CAA might reﬂect
interstitial ﬂuid drainage impairment (Weller et al., 2015), speciﬁcally
caused by accumulating leptomeningeal and superﬁcial cortical vascu-
lar amyloid-β deposition - a central event in the pathophysiology of the
disease (Arbel-Ornath et al., 2013a; Hawkes et al., 2011b; Martinez-
Ramirez et al., 2013; Roher et al., 2003). Indirect evidence for a role of
amyloid load on perivascular drainage impairment came from a PET-
based study that suggested that high CSO PVS are associated with
higher median cortical PiB retention (Charidimou et al., 2015a).
Despite the small sample size, this PET-MRI study demonstrated this
hypothesized relationship across a wide range of cerebrovascular
amyloid deposition, in both symptomatic CAA-ICH patients and elderly
participants, who often harbor asymptomatic CAA (Charidimou et al.,
2015a).
No study so far has directly addressed the relationship between the
regional distribution of amyloid PET tracer uptake and the severity and
pattern of cognitive impairment in CAA. In a single center study using
DTI-based assessment of brain connectivity, network disturbances were
associated with worse cognitive functioning and amyloid load on PET,
providing links between vascular amyloid and impairments in white
matter connectivity (Reijmer et al., 2015). These brain network
alterations in symptomatic CAA patients worsened measurably over
just 1.3-year follow-up, progressing from posterior to frontal regions,
thought the change in amyloid PET burden during the elapsed time
period has not been investigated (Reijmer et al., 2016a). In another
study, two patients with CAA-related subacute encephalopathy with
inﬂammatory angiopathy and focal vasogenic edema had positive PiB
PET (Carmona-Iragui et al., 2016), suggesting PET might help in the
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work-up of this sometimes diﬃcult to diagnose clinical entity.
As already discussed above, serial PET amyloid imaging studies
should be applied across the spectrum of the disease and its clinical
presentations – in both CAA-ICH and non-ICH ‘early’ CAA cases or even
asymptomatic individuals. Of note, the MRI structural imaging focal
lesions represent only the tip of the iceberg of CAA damage, likely
reﬂecting advanced disease. Amyloid PET imaging measures the main
feature of CAA pathophysiology – i.e. the severity of amyloid accumu-
lation in the vessels. However, how this process leads on to other
vascular changes in of CAA that appear to be instrumental in the
pathophysiology of structural MRI lesions, including vessel wall crack-
ing, vasculopathic changes, leptomeningeal vessel vs intracortical
vessel amyloid deposition (in leading to cSS vs lobar CMBs) and cortical
network dynamics, remains largely unknown. Ample evidence now
suggests that CAA is associated with important very early large scale
brain microstructural connectivity (Reijmer et al., 2015) and physiolo-
gical alterations of vascular function/neurovascular coupling (e.g.
altered vascular reactivity) (Greenberg et al., 2014). The best estab-
lished physiological change in individuals with advanced symptomatic
CAA is reduced vasodilation to physiologic stimuli. This ﬁnding has
been demonstrated in studies measuring the functional MRI (fMRI)
blood oxygen level-dependent (BOLD) response to visual stimulation
(Dumas et al., 2012; Peca et al., 2013; van Opstal et al., 2017). A
longitudinal analysis also showed declining amplitude in BOLD re-
sponse to visual stimulation among CAA patients (Switzer et al., 2016).
The same haemodynamic measures were recently found to be impaired
(compared to elderly healthy controls) in 12 pre-symptomatic carriers
with hereditary cerebral haemorrhage with amyloidosis–Dutch type
(van Opstal et al., 2017). These presymptomatic mutation carriers often
do not show CMBs, ICH or cSS. These novel ﬁndings suggest that
vascular reactivity and other physiological markers might be useful
early surrogates of vascular amyloid pathology in sporadic CAA (Smith,
2017).
Integrating all the diﬀerent observations discussed, a well-designed
study of serial amyloid PET in combination with fMRI as a measure of
cerebrovascular reactivity across the diﬀerent stages of CAA will be
important to perform. CAA is conceptualized as a protein-elimination
failure arteriopathy (Carare et al., 2013) setting in motion a self-
reinforcing loop (a “feed-forward loop” of reducing drainage eﬃ-
ciency): gradual vascular amyloid-β accumulation leads to impaired
vascular physiology, which further increases vascular amyloid-β accu-
mulation (Arbel-Ornath et al., 2013b; Hawkes et al., 2011a). A serial
PET-advanced imaging study will demonstrate in vivo the complex
interplay and extent to which cerebrovascular amyloid alters vascular
physiology and vice versa during follow-up, as well as if these defects
trigger clinically relevant haemorrhagic (Zhao et al., 2015) and
ischemic brain injury (Reijmer et al., 2016c).
Several studies not included in our systematic review because they
did not focus on cohorts of CAA patients, looked at diﬀerent correla-
tions between SVD imaging markers and PET-based amyloid burden in
diverse populations (Kim et al., 2016; Yates et al., 2014; Ye et al.,
2015). These data might be informative for presumed mechanisms of
SVD MRI markers in general, but it is very challenging to extrapolate
them in ‘pure CAA’ and assess their direct relevance. The main
challenge stems from the included populations being only health
elderly, memory clinic patients, vascular dementia patients etc. in
which codominant Alzheimer's disease pathology in likely high and the
clinical context/pretest probability very diﬀerent compared to CAA
patients.
5. Conclusions and future perspectives
Amyloid PET has provided important insights in the clinical
relevance and pathophysiological mechanisms of CAA. Our systematic
review demonstrates that only small-scale studies have been published
so far: (a) for the diagnostic utility, ﬁndings seems to be largely
consistent, at least in the limited setting that have been tested, but still
with several limitations; (b) mechanistic studies provide proof-of-
concept data for the direct association between amyloid PET burden
and small vessel disease brain injury in CAA, but require validation.
In a nutshell, amyloid PET imaging has ‘diagnostic utility’ (currently
tested only in probable CAA): it helps rule out CAA if negative, whether
compared to healthy controls or to hypertensive deep ICH controls.
However, if positive, diﬀerentiation from underlying incipient AD can
be challenging. So far no approach (regional values, ratios, visual
assessment) seems suﬃcient and speciﬁc enough to discriminate
eﬃciently CAA from AD, which may in part reﬂect the neuropatholo-
gical overlap between these two amyloidopathies. Pending validation,
combining early- and late-phase PiB images could potentially prove
helpful towards diﬀerentiating CAA from AD in case of late PiB
positivity, as depicted in the suggested workup algorithm shown in
Fig. 4. This algorithm, based on currently available evidence as
extensively discussed here, provides an operational framework for
future work on, and should be seen only as a step forward towards,
the clinical use of amyloid PET in CAA. Prospective studies in isolated
lobar ICH (“possible CAA”) and in borderline situations (see above) are
now warranted. Another potential new avenue in the diﬀerentiation
between ‘pure’ CAA and AD/mixed AD-CAA could be dual amyloid and
tau PET ligands.
Table 5
Open questions to be addressed in future studies of amyloid PET imaging in CAA.
Diagnosis
− What is the clinical diagnostic yield (sensitivity/speciﬁcity) of late-phase amyloid
PET in suspected CAA?
o In probable CAA-related strictly lobar ICH vs strictly deep non-CAA ICH
o In probable CAA-related strictly lobar ICH vs young healthy controls
− Can amyloid PET help in more deﬁnite underlying CAA diagnosis in uncertain
cases/possible CAA?
o Patients with only one lobar ICH (possible CAA)
o Mixed ICH cases
o CAA Patients presenting without major lobar ICH, especially those with 1–2
lobar CMBs or focal cortical superﬁcial siderosis
− What is the relationship between visual rating of PET +/− scans and amyloid
PET cut-oﬀs for diagnostic classiﬁcation of CAA cases?
− How can early-phase amyloid PET be combined with late phase PET,
incorporating diﬀerent regional patterns of amyloid binding in an evidence-based
diagnostic algorithm?
− How does the amyloid PET proﬁle compare to the CSF amyloid and tau proﬁles?
− Is amyloid PET potentially useful to help diagnose CAA-related inﬂammation,
thus avoiding brain biopsy?
− How amyloid PET imaging may address novel research criteria for CAA and be
incorporated with other biomarkers of the disease without the need of
neuropathological investigation?
Prognosis
− Is amyloid PET useful for clinical prognosis in CAA patients?
o For informing risk stratiﬁcation of incident/recurrent lobar ICH
o For predicting the risk of new onset CAA-related dementia, including post-ICH
dementia?
− Can amyloid PET be used as a putative biomarker in CAA therapeutic trials?
o For patient selection as a molecular signature of the disease
o For monitoring treatment eﬀects (e.g. decrease in amyloid burden)
Mechanisms
− Does amyloid PET hold promise in monitoring the natural history of CAA, i.e.
temporal patterns of amyloid accumulation?
− How reliable is amyloid PET in revealing the underlying pathophysiology of the
disease, mechanisms, risk factors and rate of amyloid vessel deposition in
longitudinal studies?
− How does amyloid PET burden and patterns (globally and focally) relate to the
other MRI markers of CAA-related brain damage across the spectrum of clinical
presentations (ICH and non-ICH), including cerebral microbleeds, cortical
superﬁcial siderosis, cortical microinfarcts and white matter hyperintensities
patterns (e.g. posterior predominance)?
− How does amyloid PET help address the AD vs CAA contributions to subcortical
vascular cognitive impairment?
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Amyloid PET is an important tool to investigate the pathophysiol-
ogy of CAA and its various manifestations including key MRI lesions
and large scale physiological alterations. Amyloid PET imaging should
also be useful to select patients for drug trials in CAA, and as an
outcome marker to monitor eﬀects of therapy. This will be particularly
relevant for early-phase studies aimed at reversing or preventing
vascular amyloid deposition. Development of a molecular imaging
tracer speciﬁc for vascular amyloid can certainly be a milestone in
the ﬁeld and preclinical studies continue to explore possible candidates
(Jia et al., 2015, 2014).
Together with the insights provided in our paper, Table 5 sum-
marizes key open questions to be addressed in future studies of amyloid
PET imaging in CAA, which will help develop and optimize strategies in
the ﬁeld with the potential to be extended in other forms of SVD.
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